RxDoctor Payments Data

Robert Farley

Nurse Practitioner · Little Rock, ARNPI 1942660980

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 149 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$701
  • Abbott$288
  • E.r. Squibb & Sons, L.L.C.$285
  • Johnson & Johnson$169
  • Amgen$161
  • Boston Scientific$160
  • plus $543 from 14 others

What the payments were for

  • Food & beverage$2,26298%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 80th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$166,219
Medicare patients
954
Services billed
3,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban542$417,746
XareltoRivaroxaban123$102,996
EntrestoSacubitril/Valsartan35$41,505
Dofetilide73$11,984
MultaqDronedarone Hcl15$11,484
SotalolSotalol Hcl388$6,593
Mexiletine Hcl40$4,783
Amiodarone Hcl312$4,186
Dabigatran EtexilateDabigatran Etexilate Mesylate17$3,507
Propafenone Hcl ErPropafenone Hcl19$3,501
Metoprolol Succinate227$2,948
Flecainide Acetate92$2,916
Propafenone Hcl32$2,221
Diltiazem 24hr Er (Cd)Diltiazem Hcl107$2,021
Diltiazem 24hr ErDiltiazem Hcl43$1,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$169$102,996123 claims
NovartisEntresto$701$41,50535 claims
Sanofi-aventis U.S. LLCMultaq$133$11,48415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →